How has Opus Genetics's accrued expenses and other liabilities changed year-over-year?

Opus Genetics's accrued expenses and other liabilities decreased by 46.0% year-over-year, from $9.11M to $4.92M.

Opus Genetics IRD Accrued expenses and other liabilities

Regeneron PharmaceuticalsREGN

$2.72B+21.5%

Taysha Gene Therapies, Inc.TSHA

——

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Operating cash flow-$12.7M-41.5%

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Opus Genetics's accrued expenses and other liabilities?: Opus Genetics (IRD) reported accrued expenses and other liabilities of $4.92M in Q1 2026.
How has Opus Genetics's accrued expenses and other liabilities changed year-over-year?: Opus Genetics's accrued expenses and other liabilities decreased by 46.0% year-over-year, from $9.11M to $4.92M.